Why we always drift lower after a press release is beyond me. Dr Moro is clearly spelling out what his agenda is after developing the new ELISA test.
Highlights:
1)This should accomplish two important objectives: The first one is to disseminate samples of the RECAF tests among many different laboratories to further evaluate, validate, and expand Biocurex’s test results. (Allows for a collection of INDEPENDENT data). The second objective is the prompt commercialization of these tests, directly by BioCurex or through its licensees.
2)BioCurex is advancing its development of a point-of-care (rapid test) which has been also been shown to work in the detection of various types of cancers. The rapid test is intended to be used at the doctor’s office and it should not be confused with ELISA, RIA or chemiluminescence, which are used in the laboratory for manual or automated testing.
Bottom line is that we CONSISTENTLY get stellar results with Recaf with ALL cancers with a variety of methods RIA, chemiluminescence, rapid test, and now ELISA.
Another key element to note is what types of cancers were identified with the new ELISA format: BioCurex is very pleased to report the results obtained using the RECAF ELISA test on 77 bladder, kidney, stomach, and other types of cancers in comparison to 93 normal donor samples (of which there are currently no cancer markers).
IMO the door will be slamming closed to buy shares at these levels in the near future. If anyone sees any negative reason not to hold their shares or not to add to their position I would like to hear from you.
News 
Market Data 
Discover 
AI
